Our top pick for
Aurora Cannabis Inc (ACB) is a leading drug manufacturers-specialty & generic business based in the US. It opened the day at USD$N/A after a previous close of USD$N/A. During the day the price has varied from a low of USD$N/A to a high of USD$N/A. The latest price was USD$N/A (25 minute delay). Aurora Cannabis is listed on the NYSE and employs 2,731 staff. All prices are listed in US Dollars.
|52-week range||USD$3.71 - USD$19.25|
|50-day moving average||USD$12.2009|
|200-day moving average||USD$8.7584|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.216|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Aurora Cannabis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aurora Cannabis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aurora Cannabis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Aurora Cannabis shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Gross profit TTM||USD$-33,539,000|
|Return on assets TTM||-6.24%|
|Return on equity TTM||-80.04%|
|Market capitalisation||USD$2.2 billion|
TTM: trailing 12 months
There are currently 19.2 million Aurora Cannabis shares held short by investors – that's known as Aurora Cannabis's "short interest". This figure is 42.2% down from 33.2 million last month.
There are a few different ways that this level of interest in shorting Aurora Cannabis shares can be evaluated.
Aurora Cannabis's "short interest ratio" (SIR) is the quantity of Aurora Cannabis shares currently shorted divided by the average quantity of Aurora Cannabis shares traded daily (recently around 35.6 million). Aurora Cannabis's SIR currently stands at 0.54. In other words for every 100,000 Aurora Cannabis shares traded daily on the market, roughly 540 shares are currently held short.
However Aurora Cannabis's short interest can also be evaluated against the total number of Aurora Cannabis shares, or, against the total number of tradable Aurora Cannabis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurora Cannabis's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Aurora Cannabis shares in existence, roughly 100 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aurora Cannabis shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurora Cannabis.
Find out more about how you can short Aurora Cannabis stock.
We're not expecting Aurora Cannabis to pay a dividend over the next 12 months.
Aurora Cannabis's shares were split on a 1:12 basis on 11 May 2020. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurora Cannabis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aurora Cannabis shares which in turn could have impacted Aurora Cannabis's share price.
Over the last 12 months, Aurora Cannabis's shares have ranged in value from as little as $3.71 up to $19.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Aurora Cannabis's is 3.1973. This would suggest that Aurora Cannabis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories, including valves, screens, etc.; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and ROAR Sports. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.